NCT05286281View on ClinicalTrials.gov

A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

May 26, 2022

Study Completion Date

May 26, 2022

Conditions
Healthy
Interventions
DRUG

PF-07265803

PF-07265803 is a p38 inhibitor formulated for oral delivery.

Trial Locations (1)

53704

Labcorp Clinical Research Unit, Madison

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05286281 - A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803 | Biotech Hunter | Biotech Hunter